Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 in Immunocompromised Participants
NCT04895982Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Oct 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04895982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895982.